Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders... Show more
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
A.I.dvisor tells us that CELU and TELO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and TELO's prices will move in lockstep.
| Ticker / NAME | Correlation To CELU | 1D Price Change % | ||
|---|---|---|---|---|
| CELU | 100% | -8.20% | ||
| TELO - CELU | 28% Poorly correlated | N/A | ||
| NVCT - CELU | 27% Poorly correlated | +0.49% | ||
| PRAX - CELU | 27% Poorly correlated | -0.94% | ||
| RNAC - CELU | 26% Poorly correlated | +1.64% | ||
| HYPD - CELU | 26% Poorly correlated | N/A | ||
More | ||||
CELU moved above its 50-day moving average on August 18, 2026 date and that indicates a change from a downward trend to an upward trend. In of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where CELU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 12, 2026. You may want to consider a long position or call options on CELU as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CELU just turned positive on August 13, 2026. Looking at past instances where CELU's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for CELU crossed bullishly above the 50-day moving average on August 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in of 246 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 87 cases where CELU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for CELU moved out of overbought territory on September 04, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CELU broke above its upper Bollinger Band on August 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CELU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.672) is normal, around the industry mean (20.572). P/E Ratio (0.000) is within average values for comparable stocks, (27.551). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.538). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (1.620) is also within normal values, averaging (444.169).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.